1 / 9

3D (Paritaprevir-Ritonavir- Ombitasvir + Dasabuvir) +/- RBV in GT1b PEARL-II

Phase 3. Treatment Experienced. 3D (Paritaprevir-Ritonavir- Ombitasvir + Dasabuvir) +/- RBV in GT1b PEARL-II. Andreone P, et al. Gastroenterology. 2014;147:359-65. 3D (Paritaprevir-Ritonavir-Ombitasvir + Dasabuvir) + /- RBV in GT1b PEARL - II: Study Design.

xiujuan-ye
Download Presentation

3D (Paritaprevir-Ritonavir- Ombitasvir + Dasabuvir) +/- RBV in GT1b PEARL-II

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Phase 3 TreatmentExperienced 3D (Paritaprevir-Ritonavir-Ombitasvir + Dasabuvir) +/- RBV in GT1bPEARL-II Andreone P, et al. Gastroenterology. 2014;147:359-65.

  2. 3D (Paritaprevir-Ritonavir-Ombitasvir + Dasabuvir) +/- RBV in GT1bPEARL-II: Study Design Source: Andreone P, et al. Gastroenterology. 2014;147:359-65.

  3. 3D (Paritaprevir-Ritonavir-Ombitasvir + Dasabuvir) +/- RBV in GT1bPEARL-II: Regimens 0 12 24 Week 3D + Ribavirin n = 91 SVR12 3D SVR12 n = 95 3D =Paritaprevir-Ritonavir-Ombitasvir + Dasabuvir Drug Dosing3D = Paritaprevir-Ritonavir-Ombitasvir (150/100/25 mg once daily)+ Dasabuvir: 250 mg twice dailyRibavirin (RBV): weight-based and divided bid (1000 mg/day if < 75kg or 1200 mg/day if ≥ 75kg) N =14 Source: Andreone P, et al. Gastroenterology. 2014;147:359-65.

  4. 3D (Paritaprevir-Ritonavir-Ombitasvir + Dasabuvir) +/- RBV in GT1bPEARL-II: Baseline Characteristics Source: Andreone P, et al. Gastroenterology. 2014;147:359-65.

  5. 3D (Paritaprevir-Ritonavir-Ombitasvir + Dasabuvir) +/- RBV in GT1bPEARL-II: Results PEARL-II: SVR 12 Rates* 85/88 91/91 *Primary endpoint by intention-to-treat analysis 3D = Paritaprevir-Ritonavir-Ombitasvir + Dasabuvir Source: Andreone P, et al. Gastroenterology. 2014;147:359-65.

  6. 3D (Paritaprevir-Ritonavir-Ombitasvir + Dasabuvir) +/- RBV in GT1bPEARL-II: Results by Prior Treatment Response PEARL-II: Results by Prior Treatment Response 85/88 91/91 29/31 32/32 24/25 26/26 32/32 33/33 Source: Andreone P, et al. Gastroenterology. 2014;147:359-65.

  7. 3D (Paritaprevir-Ritonavir-Ombitasvir + Dasabuvir) +/- RBV in GT1bPEARL-II: Treatment-Emergent Adverse Effects Source: Andreone P, et al. Gastroenterology. 2014;147:359-65.

  8. 3D (Paritaprevir-Ritonavir-Ombitasvir + Dasabuvir) +/- RBV in GT1bPEARL-II: Conclusions Note: ABT-450 = Paritaprevir Source: Andreone P, et al. Gastroenteroly. 2014;147:359-65.

  9. This slide deck is from the University of Washington’s Hepatitis C Online and Hepatitis Web Study projects. Hepatitis C Onlinewww.hepatitisc.uw.edu Hepatitis Web Studyhttp://depts.washington.edu/hepstudy/ Funded by a grant from the Centers for Disease Control and Prevention.

More Related